24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
PALBOLIEVA 125MG is an Capsule medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | PALBOLIEVA 125MG |
|---|---|
| Composition | Palbociclib Capsules 125mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsule |
| Packaging | Btl (21 cap) |
| Country of Origin | India |
PALBOLIEVA 125MG (Palbociclib Capsules 125mg) is a widely used Capsule medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
PALBOLIEVA 125 MG (Palbociclib Capsules 125 mg) is a prescription targeted anticancer medicine containing Palbociclib 125 mg, an advanced CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used primarily for the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed as part of combination therapy with hormonal treatments to help slow cancer growth and improve treatment outcomes.
Breast cancer is one of the most common cancers affecting women worldwide. Certain breast cancers depend on hormones such as estrogen and progesterone for growth. In these cancers, abnormal cell cycle activity can cause uncontrolled tumor growth and disease progression. PALBOLIEVA 125 MG works by targeting proteins known as CDK4 and CDK6, which play a critical role in cell division and cancer cell proliferation.
By blocking these proteins, Palbociclib helps stop cancer cells from progressing through the cell cycle, thereby slowing tumor growth and delaying disease progression. This targeted mechanism has transformed the treatment landscape for HR-positive, HER2-negative advanced breast cancer and has become a standard component of modern oncology care.
Unlike conventional chemotherapy, Palbociclib specifically targets cancer growth pathways while working alongside hormone therapies such as aromatase inhibitors or fulvestrant. This precision-based approach allows for more effective disease control while helping maintain quality of life.
PALBOLIEVA 125 MG is commonly prescribed for:
The medicine is typically prescribed after careful evaluation by an oncologist and may be used in different stages of advanced breast cancer treatment depending on the patient's medical condition and treatment history.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 125 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function tests, infection assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 125 MG has become an important treatment option in modern breast cancer management worldwide.
PALBOLIEVA 125 MG (Palbociclib Capsules 125 mg) is primarily used for the treatment and management of advanced hormone receptor-positive breast cancer.
The medicine is widely prescribed for patients with hormone receptor-positive, HER2-negative breast cancer.
Palbociclib helps manage breast cancer that has spread to other parts of the body.
The medicine may be used in patients with advanced disease confined to the breast and surrounding tissues.
Doctors may prescribe Palbociclib when breast cancer returns after previous treatment.
The medicine is commonly used alongside endocrine therapies to improve treatment outcomes.
Palbociclib helps slow disease progression and maintain treatment response.
The medicine supports modern precision-based breast cancer treatment strategies.
Palbociclib belongs to a class of medicines known as CDK4/6 Inhibitors.
PALBOLIEVA works by:
This targeted action helps improve disease control and supports long-term treatment outcomes.
Like all medicines, PALBOLIEVA 125 MG may cause side effects in some patients. The occurrence and severity of side effects vary among individuals.
One of the most common side effects, which may increase infection risk.
Patients may experience weakness and tiredness during treatment.
Mild to moderate nausea may occur.
Some individuals may notice mild hair loss or thinning.
Digestive disturbances may develop during therapy.
Inflammation or ulcers inside the mouth may occur.
Reduced appetite may affect nutritional intake.
The risk of infections may increase due to lowered white blood cell counts.
Some patients may experience headaches during treatment.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of PALBOLIEVA 125 MG (Palbociclib Capsules 125 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to disease characteristics.
Regular blood counts help guide dosage adjustments.
Doctors may modify therapy according to effectiveness and tolerability.
Liver and kidney health may influence treatment decisions.
Other medicines may require dosage modifications due to interactions.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, over-the-counter drugs, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically advised by a healthcare professional.
It is primarily used for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
Palbociclib is a targeted anticancer medicine that blocks CDK4 and CDK6 proteins involved in cancer cell division.
No. It is a targeted therapy known as a CDK4/6 inhibitor and works differently from traditional chemotherapy.
It is usually prescribed in combination with hormone therapies such as aromatase inhibitors or fulvestrant.
Palbociclib can lower white blood cell counts, making regular monitoring essential.
Yes. Reduced white blood cell counts may increase susceptibility to infections.
Treatment duration depends on disease response, patient tolerance, and the oncologist's recommendations.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and breast cancer treatment.